摘要
本试验用单盲安慰剂自身对照法对43例频发室性早搏(下简称室早)进行了口服恩卡尼(英卡胺,Encainide)(平均125mg/日)的临床研究。恩卡尼抑制室早、室性心动过速(下简称室速)分别65%和83%有效。恩卡尼治疗使P波宽度、PR、QRS和QT_c分别延长28%、26%、29%和7%,对JT_c,心率和左室射血分数的影响无统计学意义。7%的患者发生致心律失常作用,非心脏方面的副作用主要是头晕和视觉障碍。
Forty-three patients suffering from chronic ventricular premature complexes(VPCs/H≥60) were treated with oral encainide (av. 125mg/day) in a single blind placebo-controlled study. Encainide was effective in 28 patients (65%, 28/43) with increase of P, PR, ORS and QTc by 28% (p<0.001), 26% (p<0.001), 29% (p<0.001) and 7% (p<0.001), respectively. Encainide had no effect on JTc, HR and LVEF. The incidence of proarrhythmia was 7% (3/43)while that of other side effect such as dizziness and blurred vision was 37% (16/43).
出处
《中国循环杂志》
CSCD
1993年第1期8-9,共2页
Chinese Circulation Journal
关键词
恩卡尼
心律失常
Encainide
Ventricular-arrhythmias
